















What is the purpose of MAP?	
The Measure Applications Partnership (MAP) aims to drive progress toward national healthcare priorities.	
MAP advances this goal by recommending measures to use in federal programs.	
NATIONAL QUALITY FORUM	9











































Decision Category	Evaluation Criteria
Support for Rulemaking	The measure is fully developed and tested in the setting where it will be applied and meet: assessments 1-6 of the MAP Preliminary Analysis Algorithm. If the measure is in current us it also meets assessment 7.
Conditional Support for	The measure is fully developed and tested and meets assessments 1-6. MAP will provide a rationale that outlines the conditions (e.g., NQF endorsement) based on assessments 4-7
Rulemaking	(reference Table 2 below) that should be met. Ideally the conditions specified by MAP would be met before the measure is proposed for use. However, the Secretary retains policy discretion to propose the measure. CMS may address the MAP-specified conditions without resubmitting the measure to MAP prior to rulemaking.
Refine and	The measure meets assessments 1-3, but needs modifications. A designation of this
Resubmit for	decision category assumes at least one assessment 4-7 is not met. MAP will provide a
Rulemaking	rationale that outlines each suggested refinement (e.g., measure is not fully developed and tested OR there are opportunities for improvement under evaluation).
	Ideally the modifications suggested by MAP would be made before the measure is propose
	for use. However, the Secretary retains policy discretion to propose the measure. CMS may address the MAP-specified refinements without resubmitting the measure to the MAP prior to rulemaking. CMS may informally, without deliberations and voting, review these
	refinements via the "feedback loop" with the MAP. These updates may occur during the web meetings of the MAP workgroups scheduled annually in the fall.
Do Not Support for Rulemaking	The measure under consideration does not meet one or more of assessments 1-3.

Γ





Nov. 30	Coordinating Committee web meeting
Dec. 1	MUC list release
Nov. 30-Dec. 7	Public comment period #1 (timing based on MUC list release)
Dec. 12	Clinician workgroup in-person meeting
Dec. 13	PAC/LTC work group in-person meeting
Dec. 14	Hospital workgroup in-person meeting
Dec. 21-Jan. 11	Public comment period #2
Jan. 25-26	Coordinating Committee in-person meeting









